Full Text HL-93-11 ASTHMA CLINICAL RESEARCH NETWORK NIH GUIDE, Volume 21, Number 45, December 18, 1992 RFA: HL-93-11-L P.T. 34 Keywords: Asthma Treatment, Medical+ Data Management/Analysis+ National Heart, Lung, and Blood Institute Letter of Intent Receipt Date: March 1, 1993 Application Receipt Date: May 6, 1993 PURPOSE The Division of Lung Diseases invites applications for four Clinical Groups and one Data Coordinating Center to participate, with the assistance of the National Heart, Lung, and Blood Institute (NHLBI), in the establishment of a network of interactive asthma clinical research groups designed to facilitate evaluation of novel treatment methods and management strategies for asthma; and to rapidly disseminate the findings from these clinical studies to the health care community. This request for applications (RFA) is to: (1) provide a mechanism to establish and maintain the infrastructure required to perform multiple therapeutic trials of novel treatments and management strategies for asthma using common protocols with the requisite numbers of patients. Support would be provided to maintain the infrastructure with additional funds provided on a cost per patient basis for conducting clinical protocols. (2) Establish a Data Coordinating Center for the network. It is envisioned that the Clinical Groups would have significant experience and a strong history of basic and clinical research on the pathogenesis and treatment of asthma, since the program infrastructure should be built around existing research projects. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Asthma Clinical Research Network, is related to the priority areas of chronic disabling conditions and clinical prevention services. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic, for-profit, and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the Federal government. Foreign organizations are not eligible to apply and domestic applications may not include international components. Applications from minority individuals and women are encouraged. Awards for a Clinical Group and a Data Coordinating Center under this RFA will not be made to the same Principal Investigator (PI) to ensure that data analysis is done independently of data acquisition. The same institution may apply for both a Clinical Group and the Data Coordinating Center award, but the applications for each must be from different individuals. MECHANISM OF SUPPORT The administrative and funding mechanism to be used to undertake this program will be a cooperative agreement (U01), an assistance mechanism. Under the cooperative agreement, the NIH assists, supports, and/or stimulates and is substantially involved with recipients in conducting a study by facilitating performance of the effort in a "partner" role. Details of the responsibilities, relationships, and governance of a study funded under a cooperative agreement are discussed later in this document under the section Terms and Conditions of Award. FUNDS AVAILABLE An estimated four awards for Clinical Groups and one award for a Data Coordinating Center will be made under this RFA. A maximum of about $17.4 million (including direct and indirect costs) over a five-year period will be awarded for the Clinical Groups and the Data Coordinating Center. Approximately $2.5 million will be available for the first year, $3.5 million for the second year, $3.6 million for the third year, $3.8 million the fourth year and $3.9 million for the last year. It is anticipated that the award for each Clinical Group will be about $475,000 total costs for the first year and the award for the Data Coordinating Center will be about $600,000 total costs for the first year. Because the nature and scope of the research proposed in response to this RFA may vary, it is anticipated that the size of an award will also vary in all years. Future year costs will be redistributed based on the recommended protocols. Awards and level of support are dependent on the receipt of a sufficient number of applications of high scientific merit. Although this program is provided for in the financial plans of the NHLBI, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. The total project period for applications submitted in response to the present RFA may not exceed five years. The anticipated award date is September 30, 1993. At this time the NHLBI anticipates that there will be a renewed competition after five years. However, the final decision will depend upon experience with the network during the first five years as well as financial considerations. RESEARCH OBJECTIVES Background Asthma is an increasingly serious cause of morbidity and mortality in the United States. There are approximately 12 million asthmatics in this country. The disease affects both sexes and impacts all racial/ethnic groups. It is now recognized that asthma is a complex disease of varied etiology triggered by a number of factors such as allergens, drugs, chemicals, exercise, cold dry air, infections and emotions, making asthma therapy difficult and sometimes complicated. Multiple drugs are often required, including medications to treat and control symptoms (bronchodilator agents such as beta-2 adrenergic agonists, theophylline, and anticholinergics), as well as drugs thought to control the underlying process (anti-inflammatory agents such as inhaled and systemic corticosteroids, cromolyn sodium and nedocromil). Despite major advances in understanding the etiology and pathophysiology of asthma and the development of new therapeutic modalities, the prevalence, severity, and mortality from asthma have increased over the past decade in all age groups. In addition to the rise in morbidity and mortality, hospitalizations for asthma have doubled in adults and increased fivefold for children over the past 20 years. Mortality rates appear to be particularly high in urban and rural minority populations. Asthma continues to place a heavy burden on patients and their families, the health care system, and society as a whole. Therefore, new approaches are needed to help alleviate this growing problem. One important need is to establish a mechanism to allow rapid evaluation of new and existing therapeutic approaches for asthma, and for dissemination of laboratory and clinical findings to the health care community. This program seeks to accomplish this through a network of interactive asthma Clinical Groups that conduct clinical research in a coordinated and multidisciplinary setting. There are several key reasons why establishment of an asthma network would greatly accelerate clinical research: (1) The sometimes complicated clinical picture often makes it difficult to accumulate a large number of comparable patients in any one center. (2) The distribution of underlying disease processes may vary between populations and influence outcome independent of experimental treatment. (3) Uniformity in treatment protocols would decrease the variability of data and decrease the numbers of patients needed for each clinical study. (4) Results from the basic and clinical research laboratories can be rapidly disseminated to health care professionals for optimal care of the asthmatic patient. Availability of a coordinated asthma network would ensure appropriate patient categorization and bring together the necessary clinical expertise and administrative resources to conduct multiple therapeutic trials. Centralized protocols will promote high quality design, decrease the variability in supportive modalities, and reduce unnecessary or redundant support for conducting multiple independent clinical studies. A separate Data Coordinating Center will support protocol development, sample size calculations, common questionnaires, complete data analysis and overall study coordination. Objectives and Scope The objective of this program is to establish a network of interactive asthma clinical research groups to rapidly assess novel treatment methods and to ensure that these findings on optimal management of asthmatic patients are rapidly disseminated to practitioners and health care professionals. This program is intended to provide a mechanism to establish and maintain the required infrastructure to perform multiple therapeutic trials in asthmatic patients. The therapeutic trials may involve investigational drugs, approved agents not currently used, or drugs currently used in treatment of asthma. It will be advantageous for groups to have had substantial previous basic and/or clinical research experience in asthma and asthma related fields, since it is anticipated that the program infrastructure will be built around existing research projects. Although some of the characteristics of the network and experimental protocols are specified, the specific selection, prioritization and design of the various protocols remain in the hands of the investigators. A number of possible examples are listed purely for illustrative purposes. In order to rapidly conduct multiple clinical protocols to test novel therapeutic approaches for asthma, a collaborative effort will be required by approximately four Clinical Groups and one Data Coordinating Center. Participating institutions will develop and then follow uniform study protocols and use standardized data collection procedures. The collaborative protocols will be developed by a Steering Committee, composed of the Principal Investigators and the NHLBI Project Scientist. The various protocols will be subject to peer review by an uninvolved expert group. The clinical trials will proceed into their second (or implementation) phase only with the concurrence of both the awardees and the NHLBI. Study Design and Population It is envisioned that over the five year period several multicenter clinical trials will be developed and implemented by the Principal Investigators. The individual Clinical Groups within the network should emphasize clinical research that can be conducted under mutually agreed upon protocols. The study population is envisioned to be asthmatic patients encompassing a broad range of age groups and consisting of appropriate gender and minority representation with clearly defined and documented asthma. At a minimum, one third of the patient population at each clinic should be minority individuals and one half women. It is expected that each Clinical Group would have the ability to access at least 400 patients for various protocols over the five year period, but it is not envisioned that all 400 patients would necessarily be enrolled in research protocols at any one time, and it is possible that an individual patient may be involved in more than one study. Patient access may be accomplished by establishing strong links with community health groups such as HMOs, asthma clinics, or private practice physicians to ensure adequate numbers of patients for initiation of the clinical trials. Of the total patients accessible, investigators should include substantial numbers from a broad age range, as well as a description of the age distribution and characteristics of the population that they might recruit into potential clinical trials. Also, it is expected that Clinical Groups will develop plans to establish partnerships with the practicing physicians responsible for primary patient care. Applicants should propose two examples (conducted either concurrently or sequentially) of clinical protocols requiring multicenter participation that they consider important. For each example applicants should submit concept documents not more than four pages long, that briefly outline the rationale and background of the proposed clinical trials, study design, type of patients to be included in the protocols, eligibility criteria, and baseline and outcome measures. These examples should represent clinical trials that the investigators are interested in conducting, keeping in mind that the network mechanism allows using specific non-approved investigational drugs. For each of the clinical protocols, applicants should discuss the characteristics and numbers of potential patients that would be available from their own geographic area. Examples of clinical protocols appropriate to the program may include, but are not limited to: o long term evaluation of safety, efficacy, and side effects of high dose inhaled steroids in the treatment of moderate to severe asthma, including the effects on airways responsiveness, growth, bone density, pituitary and adrenal axis function; o efficacy of alternative anti-inflammatory therapies (e.g., methotrexate, gold) in the treatment of chronic asthma; the role of 5-lipoxygenase inhibitors and other new agents that inhibit the final pathways in the treatment of asthma; o comparison of leukotriene antagonists and 5-lipoxygenase inhibitors with inhaled steroids; o efficacy of long acting beta-2 agonists and their interaction with inhaled steroids. The topics for the network protocols will be proposed and prioritized by the steering committee, but the actual number of clinical trials conducted will be dependent upon availability of funds. It is anticipated that many of the initial network protocols will be selected from among those proposed by the successful applicants. Timetable The timetable for the study may be roughly subdivided into three phases over a five year period. There may be some overlap of functions within each of the phases, and the time estimates are only approximations. The purpose of the phases is to provide broad guidelines of the total scope of work to be accomplished for this RFA. Phase I: Planning and development of the network infrastructure, protocol development 0-12 months Phase II: Patient recruitment, protocol implementation, further protocol development 12-60 months Phase III: Data analysis, report preparation, protocol development and recruitment for next studies 24-60 months The first twelve months of the study may be devoted to planning and development of the network infrastructure and committee structure. Possible objectives for the planning and development stage are to select a steering committee chairperson; determine patient eligibility criteria for initial clinical trials; train staff in diagnostic procedures; help set up data acquisition and consent forms; define terms and outcome measures; develop a manual of operations, questionnaires, procedures for quality control, determine priorities for protocol development and begin to develop specific protocols. The Principal Investigators, through the Steering Committee, will lead the planning effort, with the assistance of the Project Scientist at NHLBI. Key Clinical Group staff may also be involved in the planning. Subcommittees of the Steering Committee may be formed to help in this effort. The Data Coordinating Center will also play a key role in the planning and development stage. Possible objectives for the planning and development stage for the Data Coordinating Center, in addition to assisting Clinical Groups in their planning and organization of the network, are to help develop study protocols, randomization and analytic plans; select a data acquisition, transfer, and management system; plan for any subcontracts for chemical analysis; develop procedures for quality control, training, and certification; print the protocols and data forms; develop and produce a Manual of Operations, and take the lead for the orderly accumulation and transmission of data for the network. In Phase II, the Clinical Groups will select and prioritize common protocols for the network, proceed with subject recruitment and protocol implementation for the first studies and concurrent development of additional protocols. Possible objectives for Phase II for the Data Coordinating Center are to assist the Clinical Groups with respect to completing protocol development, patient recruitment, randomization, data acquisition, and ongoing quality control. In Phase III, after the last patients in the first study have completed their follow-up measurements, Clinical Groups will review their data and assist the Data Coordinating Center in the closeout of the initial study. Initiation of patient accrual will begin for the next studies and protocol development continues for subsequent trials. The Data Coordinating Center will continue with its activities in data management, editing, data analysis and protocol development. It will also support manuscript preparation through data analysis, statistical consultation, editorial tasks, and coordination of meetings. It is anticipated that the main results paper for each network clinical trial will be collaboratively prepared by the investigators and submitted for publication. SPECIAL REQUIREMENTS Additional Material to Include in the Application To promote the development of a collaborative program among the award recipients, a number of issues discussed below need to be addressed in each application for a Clinical Group. Each application should discuss the qualifications and experience of the investigators. It is envisioned that the Principal Investigator will be an established investigator with experience in conducting multicenter trials that include patients, physicians, and the community. It is anticipated that the program infrastructure will be built around existing research projects. Therefore, applicants should have a substantial base of funded research in asthma or asthma related fields. The level of this current research support (direct costs per year) and past record of achievement in research related to the pathogenesis and treatment of asthma should be discussed as well as the laboratory/clinical facilities available at their institutions, and the facilities at any proposed participating subcontracting organizations. For any subcontracts, especially for access to asthma patients, there should be a description of the organization of that facility including the means of assuring quality control of patient care as well as data entry, plans for coordination, and a process for filing patient assurances. Also, plans for accessing at least 400 asthmatic patients encompassing a broad range of age groups, and consisting of appropriate gender and minority representation with clearly defined and documented asthma for use over the five year period should be detailed in the application. These plans should outline links between individual Clinical Groups and community health groups. In addition, applicants should provide a brief description of the patient characteristics, age distribution, and any other relevant baseline information of the patient population. It is anticipated that the patient population will consist of about one third minority groups and one half women. The patient population available to investigators should be recruited primarily from within a clinic's immediate geographic area, and include a substantial number of patients covering a broad age range. As part of these community based contacts, clinics should discuss potential approaches to disseminate new knowledge gained from these clinical studies to various health care groups. Applicants should also discuss their willingness, and that of the institutions involved, to pursue capitation of operational costs for each protocol, and general support of collaborative research through this network concept. Clinical Group applicants must be able to interact effectively with the Data Coordinating Center to transmit and edit data and should discuss their capability to participate in a distributed data entry system if this approach is selected. Clinical Group applicants should also state their willingness to participate in a cooperative and interactive manner with other Clinical Groups, the NHLBI and the Data Coordinating Center within the context of the network. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC Program Director or Principal Investigator should be included with the application. Data Coordinating Center applicants should discuss various aspects of study design that would be important in developing asthma clinical protocols; their familiarity with asthma and other pulmonary diseases, eligibility criteria, methods of randomization, important considerations for making sample size and power calculations, baseline and outcome measures, other relevant measures including objective outcome measures of asthma, methods and frequency of data collection and entry, monitoring accuracy of data collection, methods of data acquisition and transfer, quality control procedures including training and certification, chemical analysis of blood samples, and plans for statistical analysis of results. Budget and Related Issues The underlying concept of this network is that a core effort is essential to maintain the infrastructure required to perform multiple therapeutic trials in asthma. Based on this approach we estimate that the individual Clinical Groups will require a minimum level of effort to sustain the organizational aspects of the network. Therefore, individual Clinical Groups should submit requests for a BASE BUDGET, not to exceed $125,000 total costs per year, for the organizational aspects of the network over five years. The suggested level of commitment to maintain the infrastructure for each year may be in the order of 10 percent for the Principal Investigator, five percent for the co-investigator, 25 percent for a secretary, 100 percent for a clinical coordinator, and travel costs for approximately four trips to Bethesda for two people. Additional support (in the range of $350,000 total costs for the first year per clinic) will be provided on a per patient basis for conducting the actual clinical protocols. Applications for the Clinical Groups and Data Coordinating Center should present five budget periods of 12 months each. For the Clinical Groups, budgets for the first twelve months should include the base costs and a budget for only one of the proposed clinical trials that is outlined in the application for the duration of the proposed trial. The budget for the clinical protocol should be developed on a cost per patient basis and include all direct and any applicable indirect costs. Capitation costs should not include funds for investigational drugs. However, any approved drugs or laboratory tests should be part of the per patient cost of conducting a protocol. Applicants should identify the potential source(s) for any drugs or substances that are being considered for clinical protocols that are currently unavailable commercially. Investigators should only prepare budgets for their own Clinical Group and not for the entire network. Applicants should also indicate whether the capitation costs for the second protocol included in the application will be similar or markedly different (if so by how much) from the sample budget. Only the base budget should be escalated four percent for the remaining future years. It is not the intent of this network to provide support for only a single protocol that runs for the entire five years. Ongoing annual budgets of the Clinical Groups within the asthma network will be based on individual recommended protocols that will be funded through a capitation funding mechanism. Each Clinical Group will be given base costs as defined above and in addition, a flat fee per patient successfully enrolled and completed as defined. Future year costs will be redistributed based on the recommended protocols. The individual clinics will be expected to project patient enrollment for a specific protocol during a specified time frame; continuation and level of funding will be based on actual recruitment and overall performance. Applicants for the Data Coordinating Center should prepare budgets that roughly correspond with the standard coordinating center responsibilities related to the above mentioned network phases. These awards will be subject to administrative review annually. It should be recognized that not all clinical protocols proposed or recommended may be done, and it is possible that not all clinics would be participating equally in all protocols. Given the current resources and range of anticipated costs, it is possible that the network may be able to simultaneously conduct between two and four simple protocols per year. However, availability of funds and ability to recruit the required patients will determine the actual numbers of protocols that can ultimately be accomplished through the network. The protocols of successful applicants will be submitted to the Steering Committee for further consideration once the cooperative agreements have been awarded. It is anticipated that many of the initial network protocols will be selected from among those highly meritorious studies proposed by the successful applicants. However, a decision to fund a particular Clinical Group will not commit the network to develop that group's clinical protocol. Study Organization Steering Committee The Steering Committee will be the main governing body of the network and, at a minimum, will be composed of the PIs of each Clinical Group, the Principal Investigator of the Data Coordinating Center, and the NHLBI Project Scientist (Branch Chief, Airways Diseases Branch, Division of Lung Diseases). Each Clinical Group, the Data Coordinating Center and the NHLBI will have one vote. The Committee may meet as often as four to six times in the first 12 months of the study and two to four times per year thereafter. All major scientific decisions will be determined by majority vote of the Steering Committee. The Chairperson, who will be someone other than an NHLBI staff member, should be selected by the end of the second meeting of the Steering Committee. The first meeting of the Steering Committee will be convened by the NHLBI Project Scientist. The Steering Committee will have primary responsibility for developing common clinical protocols, facilitating the conduct and monitoring of the studies, and reporting the study results. Topics for the protocols will be proposed and prioritized by the Steering Committee. In certain instances, FDA cooperation may be sought in protocol development, especially if unconventional interventions are being considered. Subcommittees of the Steering Committee will be established as necessary. The NHLBI will have one voting representative on each subcommittee. The collaborative protocols will be developed by the Steering Committee. With data submitted centrally to the Data Coordinating Center, the protocols will define rules regarding access to data and publications. An independent Data and Safety Monitoring Board, to be appointed by NHLBI, will review progress at least annually and report to NHLBI. Terms and Conditions of Award The administrative and funding mechanism to be used to undertake this project will be cooperative agreements (U01), an assistance mechanism. Under the cooperative agreement, the NIH assists, supports and/or stimulates, and is involved substantially with recipients in conducting a study by facilitating performance of the effort in a "partner" role. Consistent with this concept, the tasks and activities in carrying out the studies will be shared among the awardees and the NHLBI Project Scientist. The tasks or activities in which awardees have substantial responsibilities include protocol development, participant recruitment and follow-up, data collection, quality control, interim data and safety monitoring, final data analysis and interpretation, preparation of publications, collaboration with other awardees, and collaboration with the NHLBI Project Scientist. The NHLBI Project Scientist will have substantial responsibilities in protocol development, quality control, interim data and safety monitoring, final data analysis and interpretation, preparation of publications, collaboration with awardees, and coordination and performance monitoring. It is anticipated that awardees will have lead responsibilities in study design, protocol development, final data analysis and interpretation, and the preparation of most publications. It is anticipated that the NHLBI Project Scientist will have lead responsibilities in quality control and catalyzing interim monitoring of data and safety and may, consistent with publication policy to be adopted by the Steering Committee, have lead responsibilities in the preparation of some publications. The NHLBI Project Scientist will have voting membership on the Steering Committee, and as appropriate, its subcommittees. Awards resulting in response to this RFA are for five years for the Clinical Groups and Data Coordinating Center. Awardees will retain custody of and have primary rights to their data developed under these awards, subject to Government, e.g., NHLBI, NIH, or PHS, rights of access consistent with current HHS, PHS, and NIH policies. The NHLBI reserves the right to terminate or curtail the study (or an individual award) in the event of (a) substantial shortfall in participant recruitment, follow-up, data reporting, quality control, or other major breech of the protocol, (b) substantive changes in the agreed-upon protocol to which the NHLBI does not agree, (c) reaching a major study endpoint substantially before schedule with persuasive statistical significance, or (d) human subject ethical issues that may dictate a premature termination. Any disagreement that may arise in scientific matters between award recipients and the NHLBI may be brought to arbitration. An arbitration panel will be composed of three members--one selected by the Steering Committee (with the NHLBI member not voting) or by the individual awardee in the event of an individual disagreement, a second member selected by NHLBI, and the third member selected by the two prior members. This special arbitration procedure in no way affects the awardee's right to appeal an adverse action that is otherwise appealable in accordance with the PHS regulations at 42 CFR part 50, subpart D and HHS regulation at 45 CFR part 16. These special Terms of Award are in addition to and not in lieu of otherwise applicable OMB administrative guidelines, HHS Grant Administration Regulations at 45 CFR part 74, and other HHS, PHS, and NIH Grant Administration policy statements. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements are required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of disease, disorder, or condition under study; special emphasis must be placed on the need for inclusion of minorities and women in studies of diseases, disorders, and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale must be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues must be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information must be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan, and summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans [including American Indians or Alaskan Natives], Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are not subject to these policies. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. LETTER OF INTENT Prospective applicants are asked to submit, by March 1, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address, and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application may be submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NHLBI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: C. James Scheirer, Ph.D. Review Branch, Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 648 Bethesda, MD 20892 Telephone: (301) 496-7363 FAX: (301) 402-1660 APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices of sponsored research; from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone (301) 496-7441; and from the NIH Project Scientist named below. The RFA label available in the application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed in line 2a of the face page of the application form and the YES box must be marked. Send or deliver the original, signed application and three legible complete photocopies to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** Send two additional copies of the application to: C. James Scheirer, Ph.D. Review Branch, Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 648 Bethesda, MD 20892 Telephone: (301) 496-7363 It is important to send these two copies at the same time as the original and that three copies are sent to the Division of Research Grants. Otherwise, the NHLBI cannot guarantee that the application will be reviewed in competition for this RFA. Applications must be received by May 6, 1993. If an application is received after this date it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS General Considerations All applicants will be judged on the basis of the scientific merit of their proposed protocols and their documented ability to conduct the essential study components as broadly outlined in the RESEARCH OBJECTIVES of this RFA. Although the technical merit of the protocol is important, it will not be the sole criterion for selection of a Clinical Group. Other considerations such as the importance and timeliness of the proposed clinical trials, access to patients, and multidisciplinary nature of the studies will be part of the evaluation criteria. Review Method Upon receipt, applications will be reviewed by the DRG for completeness and by NHLBI staff for responsiveness to this RFA. Incomplete applications will be returned to the applicant without further consideration. If the application is judged unresponsive, the applicant will be contacted and given an opportunity to withdraw the application or to have it considered for the regular, investigator-initiated grant program of the NIH. If the application submitted in response to this RFA is substantially similar to a grant application already submitted to the NIH for review, but has not yet been reviewed, the applicant will be asked to withdraw either the pending application or the new one. Simultaneous submission of identical applications will not be allowed, nor will essentially identical applications be reviewed by different review committees. Therefore, an application cannot be submitted in response to this RFA that is essentially identical to one that has already been reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. Applications judged to be responsive by NHLBI staff will be reviewed for scientific and technical merit by an initial peer review group, which will be convened by the Division of Extramural Affairs, NHLBI, solely to review these applications. The initial review will include a preliminary evaluation to determine scientific merit relative to the other applications received in response to this RFA (triage); the NIH will remove from further consideration applications judged to be noncompetitive and promptly notify the Principal Investigator and the official signing for the applicant organization. Those applications judged to be competitive will be further evaluated for scientific/technical merit by the usual peer review procedures, including, if deemed appropriate, an applicant interview in or near Bethesda at the applicant's expense. Subsequently, they will be reviewed by the National Heart, Lung, and Blood Advisory Council. Review Criteria Applicants are encouraged to submit and describe their own ideas on how best to meet the goals of the network and their specific protocols, but they are expected to address issues identified under SPECIAL REQUIREMENTS of this Request for Applications. Applications will be judged primarily on the scientific quality of the application, the appropriateness, importance and timeliness of the proposed clinical trials, facilities and access to patients, multidisciplinary nature of the study, approach to cost containment, the discussion of considerations relevant to this RFA, expertise of the investigators, their capability to perform the work proposed, and a demonstrated willingness to work as part of the network and with the NHLBI Project Scientist. The review group will assess the scientific merit of the protocols and related factors, including: Clinical Groups o Importance and scientific merit of the proposed protocols, including adequacy of the methodology to carry out the research and utilization of the multicenter nature of the network. o Adequacy of the patient population and numbers of patients, including appropriate representation of minorities and women. o Availability of adequate facilities and other resources including a plan for the administrative structure within the Clinical Group. o Rationale and cost-effectiveness of the research approach proposed. o Adequacy of data collection, preliminary analysis, and reporting procedures, including adequacy to process the volume of data expected within their Clinical Group and manage the individual study databases. Plans to ensure quality control of data. o Expertise, training, and experience of the investigators and staff, including the scientific and administrative abilities of the PI and co-investigators; their potential to accomplish the proposed research goals; the time they plan to devote to the program for the effective conduct of the study; their previous experience conducting clinical research in asthma; their ability and experience to participate in multicenter clinical trials; and willingness to work collaboratively with other Clinical Groups, the Data Coordinating Center, and the NHLBI in the manner summarized in the RFA, including implementation of common protocols within the network framework. o Facilities, equipment, and organizational structure to effectively implement the proposed research. Data Coordinating Center o Understanding of the scientific, statistical, logistical, and technical issues underlying multicenter studies, including issues related to treatment and management of asthma, and taking a leadership role in the area of study design, statistics, logistics, data acquisition and management, quality control, data analysis, and network coordination. o Adequacy of the proposed plans for acquisition, transfer, management, and analysis of data, quality control of data collection and monitoring, and overall coordination of network activities. o The expertise, training, and experience of the investigators and staff, including the administrative abilities of the Principal Investigator and co-investigators, and the time they plan to devote to the program for the effective coordination of the network. o The administrative, supervisory, and collaborative arrangements for achieving the goals of the program, including willingness to cooperate with the participating Clinical Groups and the NHLBI. o Facilities, equipment, and organizational structure to effectively assist Clinical Groups in implementing the network protocols and in data collection procedures and in overall coordination of network activities. o Appropriateness of the budget for the work proposed. AWARD CRITERIA Applications recommended by the National Heart, Lung, and Blood Advisory Council will be considered for award based upon (a) scientific and technical merit, importance of the proposed clinical trial, timeliness, multidisciplinary nature of the study, and the requirements explicitly stated in this RFA; (b) program balance, including in this instance, sufficient compatibility of features to make a successful collaborative program a reasonable likelihood; and (c) availability of funds. Letter of Intent: March 1, 1993 Application Receipt Date: May 6, 1993 Review by NHLBAC: September 2-3, 1993 Anticipated Award Date: September 30, 1993 INQUIRIES Written and telephone inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Inquiries regarding this announcement may be directed to: James P. Kiley, Ph.D. Chief, Airways Diseases Branch Division of Lung Diseases National Heart, Lung, and Blood Institute Westwood Building, Room 6A15 Bethesda, MD 20892 Telephone: (301) 496-7332 FAX: (301) 496-9886 Inquiries regarding review and application procedures may be directed to: C. James Scheirer, Ph.D. Review Branch, Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 648 Bethesda, MD 20892 Telephone: (301) 496-7363 FAX: (301) 402-1660 Inquiries regarding fiscal and administrative matters may be directed to: Mr. Raymond Zimmerman Grants Management Officer, Lung Section Grants Operations Branch Division of Extramural Affairs National Heart, Lung, and Blood Institute Westwood Building, Room 4A11C Bethesda, MD 20892 Telephone: (301) 496-4970 FAX: (301) 402-1200 AUTHORITY AND REGULATIONS This project is described in the Catalog of Federal Domestic Assistance No. 93.837. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR 74. This project is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |